12 results on '"TCDCA"'
Search Results
2. Conjugated bile acids alleviate acute pancreatitis through inhibition of TGR5 and NLRP3 mediated inflammation
- Author
-
Zi-yi Zhang, Xiu-liu Guo, Jing-tian-yi Liu, Yi-jie Gu, Xing-wei Ji, Shu Zhu, Jin-yan Xie, and Feng Guo
- Subjects
Acute pancreatitis ,Bile acid ,TGR5 ,NLRP3 inflammasome ,TCDCA ,Medicine - Abstract
Abstract Introduction Severe acute pancreatitis (SAP) is a crucial gastrointestinal disease characterized by systemic inflammatory responses and persistent multiple organ failure. The role of bile acids (BAs) in diverse inflammatory diseases is increasingly recognized as crucial, but the underlying role of BA conjugation remains elusive. Objectives Our study aim to investigate the potential role of conjugated bile acids in SAP and reveal the molecular mechanisms underlying its regulatory effects. We hypothesized that taurochenodeoxycholic acid (TCDCA) and glycochenodeoxycholic acid (GCDCA) could protect SAP through inhibiting the activation of NLRP3 inflammasomes via the TGR5 pathway in macrophages. Methods To test our hypothesis, we used BA-CoA: amino acid N-acyltransferase knockout (Baat −/− ) mice and established SAP mouse models using caerulein- and sodium taurocholate- induced. We utilized a range of methods, including pathology sections, qRT-PCR, immunofluorescence, Western blotting, and ELISA, to identify the mechanisms of regulation. Results BA-CoA: Amino acid N-acyltransferase knockout (Baat −/− ) mice significantly exacerbated pancreatitis by increasing pancreatic and systemic inflammatory responses and pancreatic damage in SAP mouse models. Moreover, the serum TCDCA levels in Baat −/− mice were lower than those in wild-type (WT) mice with or without SAP, and GCDCA and TCDCA showed stronger anti-inflammatory effects than chenodeoxycholic acid (CDCA) in vitro. TCDCA treatment alleviated SAP in a Takeda G protein-coupled receptor 5 and NOD-like receptor family, pyrin domain containing 3—dependent manner in vivo. Reinforcing our conclusions from the mouse study, clinical SAP patients exhibited decreased serum content of conjugated BAs, especially GCDCA, which was inversely correlated with the severity of systemic inflammatory responses. Conclusion Conjugated bile acids significantly inhibit NLRP3 inflammasome activation by activating TGR5 pathway, thereby alleviating pancreatic immunopathology. The results provide new insights into the variability of clinical outcomes and paves the way for developing more effective therapeutic interventions for AP.
- Published
- 2024
- Full Text
- View/download PDF
3. Conjugated bile acids alleviate acute pancreatitis through inhibition of TGR5 and NLRP3 mediated inflammation
- Author
-
Zhang, Zi-yi, Guo, Xiu-liu, Liu, Jing-tian-yi, Gu, Yi-jie, Ji, Xing-wei, Zhu, Shu, Xie, Jin-yan, and Guo, Feng
- Published
- 2024
- Full Text
- View/download PDF
4. Rapidly directional biotransformation of tauroursodeoxycholic acid through engineered Escherichia coli.
- Author
-
Shi, Jie, Wang, Jie, Yu, Lu, Yang, Li, Zhao, Shujuan, and Wang, Zhengtao
- Subjects
- *
BILE , *TAUROURSODEOXYCHOLIC acid , *BIOTRANSFORMATION (Metabolism) , *ESCHERICHIA coli , *BIOSYNTHESIS , *HYDROXYSTEROID dehydrogenases - Abstract
Bear bile powder is a precious medicinal material. It is characterized by high content of tauroursodeoxycholic acid (TUDCA) at a ratio of 1.0-1.5 to taurochenodeoxycholic acid (TCDCA). Here, we reported the biotransformation of tauroursodeoxycholic acid (TUDCA) through Escherichia coli engineered with a two-step mimic biosynthetic pathway of TUDCA from taurochenodeoxycholic acid (TCDCA). Two 7α-hydroxysteroid dehydrogenase (7α-HSDH) and two 7β-hydroxysteroid dehydrogenase (7β-HSDH) genes (named as α, α, β, and β) were selected and synthesized to create four pathway variants using ePathBrick. All could convert TCDCA to TUDCA and the one harboring α and β (pαβ) showed the strongest capability. Utilizing the oxidative and reductive properties of 7α- and 7β-HSDH, an ideal balance between TUDCA and TCDCA was established by optimizing the fermentation conditions. By applying the optimal condition, E. coli containing pαβ (BL-pαβ) produced up to 1.61 ± 0.13 g/L of TUDCA from 3.23 g/L of TCDCA at a ratio of 1.3 to TCDCA. This study provides a potential approach for bear bile substitute production from cheap and readily available chicken bile. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
5. Taurochenodeoxycholic acid induces NR8383 cells apoptosis via PKC/JNK-dependent pathway.
- Author
-
Wang, Xu, Zhang, Ziying, He, Xiuling, Mao, Wei, Zhou, Lei, and Li, Peifeng
- Subjects
- *
CHENODEOXYCHOLIC acid , *APOPTOSIS , *PROTEIN kinase C , *ANTI-inflammatory agents , *IMMUNOREGULATION - Abstract
Our former studies have suggested that taurochenodeoxycholic acid (TCDCA) as a signaling molecule shows obvious anti-inflammatory and immune regulation properties. In this research, we tentatively explored the potential effects and the possible mechanism that involve in the apoptotic process in NR8383 cells induced by TCDCA. Using flow cytometry analysis, we evaluated the apoptosis rate. Gene expression levels were determined by qPCR. The expressions of protein kinase C (PKC), Jun N-terminal kinase (JNK) and their phosphorylation were measured by Western Blot. We observed the activities of caspase-3 and caspase-8 with Caspase-Glo® regent. The results demonstrated that TCDCA dramatically improved the apoptosis rate of NR8383 cells in a concentration-dependent manner. In the meantime, PKC mRNA levels and activities were significantly augmented by TCDCA treatments. In addition, JNK, caspase-3 and caspase-8 mRNA expression levels and activities were increased by TCDCA, while they were markedly decreased by specific inhibitors. We conclude that TCDCA contributes to the apoptosis through the activation of the caspase cascade in NR8383 cells, and the PKC/JNK signaling pathway may be involved in this process. These results indicate that TCDCA may be a latent effective pharmaceutical product for apoptosis-related diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
6. 牛磺鹅去氧胆酸对 TGR5 介导的 NR8383 细胞 TNF-α 的影响.
- Author
-
王旭, 李培锋, and 张子英
- Abstract
Copyright of Chinese Journal of Veterinary Science / Zhongguo Shouyi Xuebao is the property of Chinese Society of Veterinary Science and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2016
- Full Text
- View/download PDF
7. Effect of taurochenodeoxycholic acid on EP2 receptor expression on synoviocytes of rat with adjuvant arthritis.
- Author
-
ZHANG Ting-ting, LI Pei-feng, and HE Xiu-ling
- Abstract
t:The present study investigated the influence of taurochenodeoxycholic acid (TCDCA) on EP
2 receptors on synovial fibroblast (FLS) from adjuvant arthritis (AA) rat. The FLS from AA rat were cultured in vitro and used Elisa method to measure the quantity of second messenger cAMP, in order to determine the best drug concentration of TCDCA. And then, with the treatment of TCDCA in vitro, using real time RT-PCR measured EP2 receptors expression on FLS. The resule of Elisa method indicated that after TCDCA treatment, the concentration of cAMP had asignificantly change in FLS when existence of PGE2 (10–6 mol/L), with dose-dependent. In addition, real-time RT-PCR results showed that PGE2 could promote EP2 mRNA expression in the FLS, while TCDCA(10–5 -10–7 mol/L) could significantly reduce the mRNA expression of EP2 receptors (P < 0.01). These results indicated that TCDCA may have an impact on PGE2 pathway, which may be one of a new breakthrough point for further research TCDCA biological effects. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
8. NASH-related increases in plasma bile acid levels depend on insulin resistance
- Author
-
Grzych, Guillaume, Chavez-Talavera, Oscar, Descat, Amandine, Thuillier, Dorothee, Verrijken, An, Kouach, Mostafa, Legry, Vanessa, Verkindt, Helene, Raverdy, Violeta, Legendre, Benjamin, Caiazzo, Robert, Van Gaal, Luc, Goossens, Jean-Francois, Paumelle, Rejane, Francque, Sven, Pattou, Francois, Haas, Joel T., Tailleux, Anne, Staels, Bart, Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U1011 (RNMCD), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 (GRITA), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Recherche translationnelle sur le diabète - U 1190 (RTD), University of Antwerp (UA), Antwerp University Hospital [Edegem] (UZA), ANR-16-RHUS-0006,PreciNASH,PreciNASH(2016), ANR-10-LABX-0046,EGID,EGID Diabetes Pole(2010), European Project: 694717,H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) ,ImmunoBile(2016), European Project: 32591,HEPADIP, European Project: 305707,EC:FP7:HEALTH,FP7-HEALTH-2012-INNOVATION-1,RESOLVE(2013), Derudas, Marie-Hélène, PreciNASH - - PreciNASH2016 - ANR-16-RHUS-0006 - RHUS - VALID, EGID Diabetes Pole - - EGID2010 - ANR-10-LABX-0046 - LABX - VALID, Bile acid, immune-metabolism, lipid and glucose homeostasis - ImmunoBile - - H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) 2016-09-01 - 2021-08-31 - 694717 - VALID, Hepatic and adipose tissue and functions in the metabolic syndrome - HEPADIP - 32591 - OLD, A systems biology approach to RESOLVE the molecular pathology of two hallmarks of patients with metabolic syndrome and its co-morbidities, hypertriglyceridemia and low HDL-cholesterol - RESOLVE - - EC:FP7:HEALTH2013-01-01 - 2017-12-31 - 305707 - VALID, Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires (RNMCD - U1011), and Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille
- Subjects
GHDCA ,glycolithocholic acid ,taurohyodeoxycholic acid ,OGTT, oral glucose tolerance test ,GUDCA, glycoursodeoxycholic acid ,TCDCA ,FXR, farnesoid-X-receptor ,UDCA ,ADA, American Diabetes Association ,IR, insulin resistance ,GCA, glycocholic acid ,THDCA, taurohyodeoxycholic acid ,HCA ,T2D ,LCA, lithocholic acid ,HCA, hyocholic acid ,DCA ,TCDCA, taurochenodeoxycholic acid ,GCDCA, glycochenodeoxycholic acid ,LCA ,NASH ,GCDCA ,GHCA, glycohyocholic acid ,TCA ,cholic acid ,[SDV] Life Sciences [q-bio] ,FPG ,glycoursodeoxycholic acid ,FXR ,deoxycholic acid ,glycocholic acid ,non-alcoholic steatohepatitis ,TDCA, taurodeoxycholic acid ,HbA1c ,NASH, non-alcoholic steatohepatitis ,T2D, type 2 diabetes ,Translational study ,oral glucose tolerance test ,digestive system ,BA ,UDCA, ursodeoxycholic acid ,HDCA ,glycochenodeoxycholic acid ,TUDCA, tauroursodeoxycholic acid ,NAFLD ,OGTT ,taurochenodeoxycholic acid ,NAFL, non-alcoholic fatty liver ,GCA ,FPG, fasting plasma glycaemia ,GDCA, glycodeoxycholic acid ,GLCA, glycolithocholic acid ,C4 ,bile acids ,glycodeoxycholic acid ,nutritional and metabolic diseases ,HOMA2, homeostatic model assessment 2 ,hyocholic acid ,digestive system diseases ,farnesoid-X-receptor ,DCA, deoxycholic acid ,GUDCA ,IR ,TLCA, taurolithocholic acid ,American Diabetes Association ,CDCA ,Human medicine ,ABOS, Biological Atlas of Severe Obesity ,HDCA, hyodeoxycholic acid ,[SDV]Life Sciences [q-bio] ,HOMA2 ,taurodeoxycholic acid ,taurolithocholic acid ,C4, 7alpha-hydroxy-4-cholesten-3-one ,insulin resistance ,Biological Atlas of Severe Obesity ,taurohyocholic acid ,MAFLD, metabolic associated fatty liver disease ,CA, cholic acid ,CA ,THCA ,GHDCA, glycohyodeoxycholic acid ,Diabetes ,TLCA ,glycohyocholic acid ,ursodeoxycholic acid ,TUDCA ,TDCA ,fasting plasma glycaemia ,lithocholic acid ,NAFL ,BA, bile acids ,chenodeoxycholic acid ,non-alcoholic fatty liver ,type 2 diabetes ,ABOS ,Research Article ,NAFLD, non-alcoholic fatty liver disease ,TCA, taurocholic acid ,MAFLD ,taurocholic acid ,CDCA, chenodeoxycholic acid ,metabolic associated fatty liver disease ,glycated haemoglobin ,homeostatic model assessment 2 ,Obesity ,lcsh:RC799-869 ,tauroursodeoxycholic acid ,7alpha-hydroxy-4-cholesten-3-one ,non-alcoholic fatty liver disease ,THDCA ,hyodeoxycholic acid ,ADA ,GDCA ,lcsh:Diseases of the digestive system. Gastroenterology ,HbA1c, glycated haemoglobin ,GHCA ,glycohyodeoxycholic acid ,THCA, taurohyocholic acid ,GLCA - Abstract
Background & Aims Plasma bile acids (BAs) have been extensively studied as pathophysiological actors in non-alcoholic steatohepatitis (NASH). However, results from clinical studies are often complicated by the association of NASH with type 2 diabetes (T2D), obesity, and insulin resistance (IR). Here, we sought to dissect the relationship between NASH, T2D, and plasma BA levels in a large patient cohort. Methods Four groups of patients from the Biological Atlas of Severe Obesity (ABOS) cohort (Clinical Trials number NCT01129297) were included based on the presence or absence of histologically evaluated NASH with or without coincident T2D. Patients were matched for BMI, homeostatic model assessment 2 (HOMA2)-assessed IR, glycated haemoglobin, age, and gender. To study the effect of IR and BMI on the association of plasma BA and NASH, patients from the HEPADIP study were included. In both cohorts, fasting plasma BA concentrations were measured. Results Plasma BA concentrations were higher in NASH compared with No-NASH patients both in T2D and NoT2D patients from the ABOS cohort. As we previously reported that plasma BA levels were unaltered in NASH patients of the HEPADIP cohort, we assessed the impact of BMI and IR on the association of NASH and BA on the combined BA datasets. Our results revealed that NASH-associated increases in plasma total cholic acid (CA) concentrations depend on the degree of HOMA2-assessed systemic IR, but not on β-cell function nor on BMI. Conclusions Plasma BA concentrations are elevated only in those NASH patients exhibiting pronounced IR. Lay summary Non-alcoholic steatohepatitis (NASH) is a progressive liver disease that frequently occurs in patients with obesity and type 2 diabetes. Reliable markers for the diagnosis of NASH are needed. Plasma bile acids have been proposed as NASH biomarkers. Herein, we found that plasma bile acids are only elevated in patients with NASH when significant insulin resistance is present, limiting their utility as NASH markers., Graphical abstract, Highlights • Bile acids have been studied as pathophysiological actors and biomarkers in NASH. • Plasma BAs have been reported to be higher in NASH vs. No-NASH patients. • Plasma BAs are altered in patients with T2D, IR, and obesity, risk factors for NASH. • Thus, the independent association between plasma BA increases and NASH is unclear. • NASH-associated increases in plasma BA depend on the degree of insulin sensitivity.
- Published
- 2021
- Full Text
- View/download PDF
9. Taurochenodeoxycholic acid (TCDCA) anti-inflammatory mechanism.
- Author
-
Li Pei-feng, He Xiu-ling, Guan Hong, and Jin Shao-lin
- Abstract
The article presents a study which examines the anti-inflammatory action of taurochenodeoxycholic acid (TCDCA). Researchers perform an intragastric administration of TCDCA into adjuvant arthritis rats, and measure the contents of nitric oxide (NO) and lymphotoxin-beta (LTB
4 ) of peripheral blood by fluorospectrophotometry and enzyme-linked immunosorbent assay (ELISA). Results show the relationship between the anti-inflammatory action of TCDCA and production of LTB4 and NO .- Published
- 2008
10. Toxicity and intracellular accumulation of bile acids in sandwich-cultured rat hepatocytes: role of glycine conjugates.
- Author
-
Chatterjee S, Bijsmans IT, van Mil SW, Augustijns P, and Annaert P
- Subjects
- Algorithms, Animals, Bile metabolism, Cell Separation, Cells, Cultured, Chenodeoxycholic Acid metabolism, Chromatography, High Pressure Liquid, Data Interpretation, Statistical, Glycodeoxycholic Acid metabolism, Mass Spectrometry, RNA, Messenger biosynthesis, Rats, Taurine metabolism, Taurochenodeoxycholic Acid metabolism, Taurodeoxycholic Acid metabolism, Urea metabolism, Bile Acids and Salts metabolism, Bile Acids and Salts toxicity, Glycine physiology, Hepatocytes drug effects, Hepatocytes metabolism
- Abstract
Excessive intrahepatic accumulation of bile acids (BAs) is a key mechanism underlying cholestasis. The aim of this study was to quantitatively explore the relationship between cytotoxicity of BAs and their intracellular accumulation in sandwich-cultured rat hepatocytes (SCRH). Following exposure of SCRH (on day-1 after seeding) to various BAs for 24h, glycine-conjugated BAs were most potent in exerting toxicity. Moreover, unconjugated BAs showed significantly higher toxicity in day-1 compared to day-3 SCRH. When day-1/-3 SCRH were exposed (0.5-4h) to 5-100μM (C)DCA, intracellular levels of unconjugated (C)DCA were similar, while intracellular levels of glycine conjugates were up to 4-fold lower in day-3 compared to day-1 SCRH. Sinusoidal efflux was by far the predominant efflux pathway of conjugated BAs both in day-1 and day-3 SCRH, while canalicular BA efflux showed substantial interbatch variability. After 4h exposure to (C)DCA, intracellular glycine conjugate levels were at least 10-fold higher than taurine conjugate levels. Taken together, reduced BA conjugate formation in day-3 SCRH results in lower intracellular glycine conjugate concentrations, explaining decreased toxicity of (C)DCA in day-3 versus day-1 SCRH. Our data provide for the first time a direct link between BA toxicity and glycine conjugate exposure in SCRH., (Copyright © 2013 Elsevier Ltd. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
11. Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition.
- Author
-
Vaquero J, Monte MJ, Dominguez M, Muntané J, and Marin JJ
- Subjects
- Bile Acids and Salts chemistry, Bile Acids and Salts pharmacology, Cells, Cultured, Glycine metabolism, Hepatocytes drug effects, Hepatocytes metabolism, Humans, Intestines cytology, Isoxazoles pharmacology, Liver cytology, Organ Specificity, Protein Isoforms, Receptors, Cytoplasmic and Nuclear agonists, Receptors, Cytoplasmic and Nuclear genetics, Taurine metabolism, Bile Acids and Salts metabolism, Intestinal Mucosa metabolism, Kidney metabolism, Liver metabolism, Receptors, Cytoplasmic and Nuclear metabolism
- Abstract
The farnesoid X receptor (FXR) is a key sensor in bile acid homeostasis. Although four human FXR isoforms have been identified, the physiological role of this diversity is poorly understood. Here we investigated their subcellular localization, agonist sensitivity and response of target genes. Measurement of mRNA revealed that liver predominantly expressed FXRα1(+/-), whereas FXRα2(+/-) were the most abundant isoforms in kidney and intestine. In all cases, the proportion of FXRα(1/2)(+) and FXRα(1/2)(-) isoforms, i.e., with and without a 12bp insert, respectively, was approximately 50%. When FXR was expressed in liver and intestinal cells the magnitude of the response to GW4064 and bile acids differs among FXR isoforms. In both cell types the strongest response was that of FXRα1(-). Different efficacy of bile acids species to activate FXR was found. The four FXR isoforms shared the order of sensitivity to bile acids species. When in FXR-deficient cells FXR was transfected, unconjugated, but not taurine- and glycine-amidated bile acids, were able to activate FXR. In contrast, human hepatocytes and cell lines showing an endogenous expression of FXR were sensitive to both unconjugated and conjugated bile acids. This suggests that to activate FXR conjugated, but not unconjugated, bile acids require additional component(s) of the intracellular machinery not related with uptake processes, which are missing in some tumor cells. In conclusion, cell-specific pattern of FXR isoforms determine the overall tissue sensitivity to FXR agonists and may be involved in the differential response of FXR target genes to FXR activation., (Copyright © 2013 Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
12. Progressive stages of mitochondrial destruction caused by cell toxic bile salts.
- Author
-
Schulz S, Schmitt S, Wimmer R, Aichler M, Eisenhofer S, Lichtmannegger J, Eberhagen C, Artmann R, Tookos F, Walch A, Krappmann D, Brenner C, Rust C, and Zischka H
- Subjects
- Animals, Cell Membrane Permeability drug effects, Dose-Response Relationship, Drug, Liposomes chemistry, Liver chemistry, Membrane Potential, Mitochondrial drug effects, Mitochondria, Heart chemistry, Mitochondria, Liver metabolism, Mitochondria, Liver pathology, Mitochondrial ADP, ATP Translocases isolation & purification, Mitochondrial Membrane Transport Proteins agonists, Mitochondrial Membrane Transport Proteins metabolism, Mitochondrial Membranes chemistry, Mitochondrial Membranes drug effects, Mitochondrial Permeability Transition Pore, Myocardium chemistry, Rats, Taurochenodeoxycholic Acid toxicity, Voltage-Dependent Anion Channels chemistry, Voltage-Dependent Anion Channels isolation & purification, Glycochenodeoxycholic Acid toxicity, Mitochondria, Liver drug effects, Mitochondrial ADP, ATP Translocases agonists, Taurochenodeoxycholic Acid pharmacology
- Abstract
The cell-toxic bile salt glycochenodeoxycholic acid (GCDCA) and taurochenodeoxycholic acid (TCDCA) are responsible for hepatocyte demise in cholestatic liver diseases, while tauroursodeoxycholic acid (TUDCA) is regarded hepatoprotective. We demonstrate the direct mitochondrio-toxicity of bile salts which deplete the mitochondrial membrane potential and induce the mitochondrial permeability transition (MPT). The bile salt mediated mechanistic mode of destruction significantly differs from that of calcium, the prototype MPT inducer. Cell-toxic bile salts initially bind to the mitochondrial outer membrane. Subsequently, the structure of the inner boundary membrane disintegrates. And it is only thereafter that the MPT is induced. This progressive destruction occurs in a dose- and time-dependent way. We demonstrate that GCDCA and TCDCA, but not TUDCA, preferentially permeabilize liposomes containing the mitochondrial membrane protein ANT, a process resembling the MPT induction in whole mitochondria. This suggests that ANT is one decisive target for toxic bile salts. To our knowledge this is the first report unraveling the consecutive steps leading to mitochondrial destruction by cell-toxic bile salts., (Copyright © 2013 Elsevier B.V. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.